机译:用于鉴定高选择性嘧啶-Pyrrolo-吡咯 - 吡咯 - 吡咯醇抑制剂的构象限制策略
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
PIQUR Therapeut AG Hochbergerstr 60 CH-4057 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
PIQUR Therapeut AG Hochbergerstr 60 CH-4057 Basel Switzerland;
PIQUR Therapeut AG Hochbergerstr 60 CH-4057 Basel Switzerland;
PIQUR Therapeut AG Hochbergerstr 60 CH-4057 Basel Switzerland;
PIQUR Therapeut AG Hochbergerstr 60 CH-4057 Basel Switzerland;
Univ Basel Dept Biomed Mattenstr 28 CH-4058 Basel Switzerland;
机译:用于鉴定高选择性嘧啶-Pyrrolo-吡咯 - 吡咯 - 吡咯醇抑制剂的构象限制策略
机译:面向立体化学多样性的策略,基于环丙烷的GABA构象限制:鉴定有效抑制GABA转运的有效铅
机译:分子动力学模拟和QM / mm计算揭示了I型1/2激酶抑制剂的选择性机制:分子内H键的效果和构象限制改善选择性
机译:RNAi技术的发展,选择性抑制乳腺癌中的mTORC2
机译:“疏水化”系统性siRNA载体并通过RNA干扰选择性抑制乳腺癌中mTORC2的策略
机译:构象限制II型FMS抑制剂导致发现5-甲基-N-(2-芳基-1H-苯并d咪唑基-5-基)异恶唑-4-羧酰胺类似物作为选择性FLT3抑制剂
机译:用于鉴定高选择性嘧啶-Pyrrolo-吡咯 - 吡咯 - 吡咯醇抑制剂的构象限制策略